Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Positive

Overview

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2723https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2723
Retrieved on: 
Thursday, April 18, 2024
Information
Tags: 
Community, Diagnosis, Civil service commission, Ovarian cancer, Cell death, Prevalence, Cell division, Disease, Clinical, Patient, Committee, EMA, IRIS, Agency, European, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EU
Summary
Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of ovarian cancer in the European Union on 9 December 2022.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • Upifitamab rilsodotin is composed of an antibody that binds NaPi2b and a drug called AF-HPA which prevents cell division, resulting in cell death.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
Copyright: 
2024 European Medicines Agency. All Rights Reserved.